Relative Bioavailability of LY2963016 to LANTUS After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 18 Nov 2019 Status changed from active, no longer recruiting to completed.
- 03 Oct 2019 Planned End Date changed from 27 Sep 2019 to 21 Oct 2019.
- 03 Oct 2019 Planned primary completion date changed from 27 Sep 2019 to 21 Oct 2019.